Patients with hypertension have an increased activity in the endothelin system and an increased vascular tone, which predisposes them to target organ damage. In the present study, in vitro pharmacology, real-time PCR and immunofluorescence techniques were used to show enhanced endothelin type A (ET A ) and type B (ET B ) receptor contraction and expression in the left internal mammary artery from patients with hypertension as compared to normotensive patients. These receptors may be important in the pathophysiology of hypertension.
Endothelin-1 (ET-1) is a potent vasoconstrictor peptide that is mainly produced by vascular endothelial cells. It mediates its effect via two different G-protein-coupled receptor subtypes: the ET A and ET B receptors. The ET A receptor is the dominant receptor subtype on vascular smooth muscle cells and mediates contraction. In contrast, the ET B receptor is mainly located on endothelial cells and mediates vasodilatation via the release of endothelium-derived relaxing factors. In the healthy vasculature, ET B receptors are expressed only at low levels on vascular smooth muscle cells. In pathology, such as coronary artery disease and congestive heart failure, ET B receptors on smooth muscle cells are upregulated and elicit contraction upon stimulation.
1,2 Previous results, obtained from the left internal mammary artery from patients undergoing coronary artery bypass graft surgery, showed a variation in the ET B receptor expression. 3 Only 58% of the patients had arteries that contracted when exposed to sarafotoxin 6c. 3 Other studies have shown similar irregularity in the endothelin response. 4 The cause of this variation is not known. In the current study, we hypothesize that the expression of endothelin receptors is higher in arteries from patients with hypertension than in arteries from patients with normal blood pressure.
Previous studies on the effects of hypertension on vascular endothelin receptors in humans have mainly been performed by analysing the regulation of vascular tone by administration of endogenous ET-1 in a forearm blood flow model. [5] [6] [7] To our knowledge, the current study is the first to sample the tissue from patients and undertake detailed in vitro assessment using a combination of pharmacological, immunofluorescence and molecular biological techniques.
Human left internal mammary arteries were collected from 55 patients undergoing elective coronary artery bypass graft surgery. The in vitro pharmacology experiments were performed continuously, and after reaching a number of 55, the results were divided into one group of hypertensives and one group of normotensives. The project was approved by the Ethics Committee of Lund University in Sweden. Thirty-four patients were suffering from essential hypertension and 21 patients had normal blood pressure. The group of patients with hypertension included both previously diagnosed hypertension (patients undergoing antihypertensive therapy) and hypertension diagnosed during the hospital stay for the coronary artery bypass graft surgery. Hypertension was defined according to the World Health Organization Guidelines, 2007. The patient baseline characteristics were as follows (number of normotensives (percentage)/number of hypertensives (percentage)): age (67 ± 3/67 ± 2), men (16 (76%)/27 (79%)), women (5 (24%)/7 (21%)), body mass index (26±1/26±1), diabetes (3 (14%)/9 (26%)), heart incompensation (1 (5%)/2 (6%)), left ventricular hypertrophy (7 (33%)/14 (41%)), threevessel disease (18 (86%)/31 (91%)), atherosclerosis in the ascending aorta (14 (67%)/22 (65%)) and pathological valves (5 (24%)/8 (24%)) and heredity for cardiovascular disease (10 (48%)/12 (35%)). Heart incompensation was diagnosed as reduced left ventricular ejection fraction via ultrasound, signs of incompensation at chest X-ray or clinical signs of dyspnoea or peripheral oedema. Left ventricular hypertrophy was diagnosed by transthoracic echocardiography, electrocardiography or clinically during surgery. Atherosclerosis in the ascending aorta and the heart valves was evaluated clinically during surgery.
The ET A and ET B receptor expression and vasoconstriction were compared between arteries from hypertensive and normotensive patients. In vitro pharmacology was used to examine contraction in cylindrical artery segments with an intact endothelium. First, sarafotoxin 6c, which is a selective ET B receptor agonist, was added cumulatively to obtain a concentration-response curve. Following the sarafotoxin 6c administration, ET B receptors were desensitized. 8 Cumulative concentration-response curves were thereafter constructed for ET-1. ET-1 is an agonist for both ET A and ET B receptors, but will activate ET A receptors selectively after ET B receptors have been desensitized. 8 Between two-and four-ring segments were analysed for each patient. The mean value of the response for each patient was calculated and then added to the group of results. The maximum contraction was calculated as per cent of the contractile response to 63.5 mmol per l potassium, and is denoted as E max in the text. ET A and ET B receptor mRNA expression levels were quantified by real-time PCR in endothelium-denuded arteries. The amount of endothelin receptor mRNA was calculated relative to the amount of b-actin mRNA in the same sample. ET A and ET B receptor protein expression was visualized using immunofluorescence in arteries with an intact endothelium. The staining intensities for ET A and ET B receptors were quantified in both the endothelium and the smooth muscle cell layer, using confocal microscopy. Results are presented as the means ± s.e.m. Statistical significance was accepted when Po0.05, using Student's t-test (GraphPad 4.0 and SPSS 15.0). For detailed method description for in vitro pharmacology and real-time PCR, see Wackenfors et al. The results from the present study indicate that both ET A and ET B receptors are upregulated in hypertension. Both ET-1 and sarafotoxin 6c contractions were stronger in arteries from patients with hypertension than in arteries from patients with normal blood pressure (Figures 1a and b) , while no difference could be observed in the potassiuminduced contractions (4.8±1.4 mN for hypertensives and 4.3 ± 1.2 mN for normotensives, P ¼ 0.8053). Furthermore, real-time PCR and immunofluorescence experiments showed increased expression of ET A and ET B receptor mRNA and protein, respectively, in the smooth muscle cell layer of arteries from patients with hypertension (Figures 1c-f) .
Only a limited number of studies have been performed earlier to evaluate the endothelin receptor effects in hypertensive human subjects. Lind et al. 9 showed increased ET-1 contraction in subcutaneous arteries from 15 patients with essential hypertension, which supports our findings. In a human forearm blood flow model, it was shown that ET A receptor antagonists cause a greater degree of vasodilatation in forearm vessels in patients with essential hypertension compared with normotensive subjects, 6 which is consistent with our findings of an increased contractile ET A receptor activity in Figure 1 In vitro pharmacology was used to assess the (a) endothelin-1 and (b) sarafotoxin 6c-induced contractions in the left internal mammary artery (with an intact endothelium) from patients with (n ¼ 34) and without (n ¼ 21) hypertension. Real-time PCR was used to assess the (c) ET A and (d) ET B receptor mRNA levels in endothelium-denuded arteries (n ¼ 8 for hypertension and n ¼ 10 for normotension). Immunofluorescence and confocal microscopy was used to assess (e) ET A and (f) ET B receptor staining intensity in the endothelial (EC) and smooth muscle cell layer (SMC) of intact arteries (n ¼ 8 for hypertension and n ¼ 8 for normotension). Values are presented as means±s.e.m. Statistical analyses were performed using Student's t-test, where Po0.05 was considered significant. Note the enhanced ET A and ET B receptor-mediated contraction and expression in arteries from patients with hypertension. ET A , endothelin type A receptor; ET B , endothelin type B receptor.
hypertension. The endothelin type B receptor antagonist BQ788 induced an increase in forearm resistance of normotensive subjects while it had a vasodilator action in the forearm circulation of hypertensive subjects, 5,10,11 indicating a vasoconstrictor effect of ET B receptors in hypertensive but not in normotensive individuals.
In healthy arteries, the contractile effect by endothelin receptors on smooth muscle cells is balanced by the dilatory effects by endothelin receptors on the endothelium. Both the endothelium function and ET B receptor levels on the endothelium are diminished in arteries from patients with hypertension. It is possible that a decreased endothelium function in these arteries from patients with hypertension may have led to an enhanced endothelin vasoconstriction. Indeed, the present immunofluorescence experiments demonstrate decreased ET B receptor staining intensities in the endothelial layer of arteries from patients with hypertension. Furthermore, after removal of the endothelium, the contractile effect of sarafotoxin 6c and ET-1 tended to be more pronounced (sarafotoxin 6c: E max ¼ 48±13% with endothelium and 66 ± 21% without endothelium, P ¼ 0.4828, and ET-1: 277 ± 47% with endothelium and 390 ± 72% without endothelium, P ¼ 0.2181). On the other hand, immunofluorescence experiments, in the present study, clearly demonstrate increased ET A and ET B receptor staining intensities in the smooth muscle cell layer of arteries from patients with hypertension. Taken together, decreased ET B receptor expression on the endothelial cells may contribute to the enhanced vasoconstriction in arteries from patients with hypertension, although the enhanced ET A and ET B receptor expression in the smooth muscle cells presumably plays the major role in the current setting. These findings were obtained inspite the fact that both the arteries from hypertensives and normotensives patients included in this study suffered from advanced coronary artery disease and probably generalized atherosclerosis and endothelial dysfunction.
Increased vascular endothelin receptor activity, as shown in the present study, may play a role in the development of target organ damage in patients with hypertension. Whether endothelin receptor antagonists will become part of the therapeutic armamentarium in essential hypertension and associated target organ damage remains unclear. New endothelin antagonists devoid of side effects or inhibitors of the endothelin-converting enzymes may be one possibility. 
